CoChat

Brexpiprazole

Markovic, Marija, Gallipani, Alyssa, Patel, Krina H., Maroney, Megan · 2017 · Annals of Pharmacotherapy

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To review the pharmacology and clinical data for brexpiprazole in schizophrenia and major depressive disorder (MDD). DATA SOURCES: An English-language literature search using PubMed and MEDLINE was performed using the term brexpiprazole. All articles containing human clinical trial data published up to September 2016 were evaluated for inclusion as well as information from the manufacturer's product labeling. STUDY SELECTION/DATA EXTRACTION: Phase 3 trials for brexpiprazole were evaluated. Key in vitro and animal data were incorporated into the pharmacology and pharmacokinetic sections where appropriate. DATA SYNTHESIS: Four phase 3 trials have evaluated the use of brexpiprazole as a primary therapy for schizophrenia or as an antidepressant adjunct for MDD. For its schizophrenia indication, brexpiprazole was studied in 2 placebo-controlled trials of approximately 1300 patients, with 4 mg of brexpiprazole consistently showing superiority over placebo. For MDD, brexpiprazole was compared with placebo as an adjunct to antidepressants in approximately 1000 patients who had failed trials of 1 to 3 prior antidepressants. The 2-mg and 3-mg dosages of brexpiprazole showed consistent superiority over placebo in the MDD trials. Common treatment emergent adverse effects included akathisia and weight gain. CONCLUSIONS: Brexpiprazole showed efficacy for the treatment of schizophrenia in the range of 2 to 4 mg/d and as an adjunct to antidepressant therapy in MDD when dosed at 2 to 3 mg/d. Advantages of this drug include once-daily dosing, good tolerability, and lack of effect on sexual function. Disadvantages include the lack of long-term safety data and potentially high cost.

Overview

Integrity signals

Registry

Crossref · 10.1177/1060028016678262

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 3

  1. Lehman AF, 2004, Am J Psychiatry, 161, 1
  2. Nelson C, 2015, Poster presented at: 168th American Psychiatric Association Annual Meeting
  3. Correll CU, 2015, Poster presented at: 15th International Congress on Schizophrenia Research (ICOSR)

Cited by

See all 22

Metadata

Authors
Markovic, M., Gallipani, A., Patel, K. H., & Maroney, M.
Affiliations
  • Rutgers, The State University of New Jersey, Piscataway Township, NJ, USA
  • Brooklyn Hospital Center (US)
  • Rutgers, The State University of New Jersey (US)
Corresponding author
Maroney, Megan
Venue
Annals of Pharmacotherapy
Published
2016-12-15
Volume
51
Issue
4
Pages
315-322
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2575166050
Cited by
22
References
15
Citations by year
2026: 4 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 3
FWCI
0.81
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Annals of Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
brexpiprazole, schizophrenia, major depressive disorder, atypical antipsychotics, pharmacokinetics, akathisia, weight gain, treatment-emergent adverse events, drug efficacy, sexual function
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Drug Therapy, Combination, Humans, Schizophrenia, Thiophenes, Antipsychotic Agents, Quinolones, Weight Gain, Clinical Trials, Phase III as Topic, Receptors, Dopamine D2, Receptor, Serotonin, 5-HT1A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.